![]() ![]() In the event such claim is properly made the State Comptroller shall pay over to the person or persons or estate making the claim such amount of such accumulated contributions without interest. Any accumulated contributions so deemed abandoned and transferred to the pension accumulation fund may be claimed by the persons who made such accumulated contributions or, in the event of his death, by his estate or such person as he shall have nominated to receive such accumulated contributions, by filing a claim with the State Comptroller in such form and in such a manner as may be prescribed by him, seeking the return of such abandoned contributions. ![]() The accumulated contributions of the persons so listed shall be deemed abandoned and shall be placed in the pension accumulation fund to be used for the purpose of said fund. At the expiration of six months from the date of the publication of this notice. A list of the names contained in this notice is on file and open to public inspection at the office of the New York State and Local Retirement System located at the 110 State St, in the City of Albany, New York. This notice is published pursuant to Section 109 of the Retirement and Social Security Law of the State of New York. The persons whose names and last known addresses are set forth below appear from records of the above named Retirement System to be entitled to accumulated contributions held by said retirement system whose membership terminated pursuant to Section 613 of the Retirement and Social Security Law on or before December 31, 2007. ![]() 2020 15(5): e0232253.The persons whose names and last known addresses are set forth below appear from records of the above named Retirement System to be entitled to accumulated contributions held by said retirement system whose membership terminated pursuant to Section 517-a of the Retirement and Social Security Law on or before December 31, 2007. "Role of trypsin and protease-active receptor-2 in ovarian cancer." PLOS One. Kim KK Turner R Khazan N Kodza A Jones A Singh RK Moore RG. ![]() "Development of Potent Forchlorfenurone Analogs and Their Cytotoxic Effect in Cancer Cell Lines." Sci Rep. Kim KK Singh RK Khazan N Kodza A Singh NA Jones A Sivagnanalingam U Towner M Itamochi H Turner, R Moore RG. "HE4 Overexpression by ovarian cancer promotes a suppressive tumor immune microenvironment and enhanced tumor and macrophage PD-L1 expression. Rowswell-Turner R Singh R Urh A Yano N Kim K Khazan K Pandita, R Sivagnanalingam U Hovanesian V James N Ribeiro J Kadambi S Linehan D Moore R. RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy. VIEW ALL expand_more Clinical Trials An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |